It is now established that a subgroup of non-Hodgkin's lymphoma (NHL) patients probably benefit from highdose therapy (HDT). We therefore retrospectively analyzed survival of 126 consecutive patients with large cell lymphoma (LCL) and high-intermediate (HI) or highrisk (H) age-adjusted international prognostic index (Aa-IPI). They received either standard chemotherapy (CT) (66 patients), or HDT (60 patients). Distribution of the Aa-IPI scores showed no statistical significant difference between the two treatment groups. Complete response (CR) rate was 51% for the whole series, with 41% and 62% for the standard CT group and HDT group, respectively. With a median follow-up of 63 months (range, 16 to 159), the 5-year overall survival (OS) and event-free survival (EFS) for all patients was 52% and 43%, respectively. There was a statistical significant difference in terms of survival towards the HDT group: OS at 76% vs 31%, EFS at 64% vs 24%. Patients who achieved CR with front-line therapy had a 5-year OS at 70%, while it was 34% for patients who were not in CR. These results are comparable to those reported in the literature, and strongly suggest that both initial CR achievement and HDT as front-line treatment are predictive factors for prolonged survival of patients with poor-risk LCL. Bone Marrow Transplantation (2000) 25, 35-40. Keywords: aggressive lymphoma; standard chemotherapy; high-dose therapy; complete response; survival Among non-Hodgkin's lymphomas (NHL), large cell lymphomas (LCL) have been recently well characterized in the Revised European-American Lymphoma (REAL) classification.
to improve patient outcome. [3] [4] [5] However, when tested in a prospective randomized phase III trial, none was found to be superior to CHOP, in terms of both complete response (CR) and survival. 6 Many patients with LCL still die of their disease, and the outcome is strongly related to the clinical features present at diagnosis.
The international prognostic index (IPI) clearly demonstrated that patients in high-intermediate risk (HI) and high risk (H) groups had a poor outcome when treated with conventional chemotherapy. 7 This group of patients and especially those who were 60 years of age or less, were largely included in randomized clinical trials testing highdose therapy (HDT) with hematopoeitic stem cell support as front-line treatment. In the study reported by the Groupe d'Etude des Lymphomes de l'Adulte (GELA), sequential conventional-dose chemotherapy was compared to HDT supported by autologous bone marrow transplantation (ABMT). Survival was significantly improved for HI risk and H risk patients who received HDT with ABMT. 8 The report of Gianni et al 9 also compared standard chemotherapy (MACOP-B) with high-dose sequential chemotherapy and ABMT. Although this study dealt with a favorable subgroup of patients, CR rate and survival were significantly improved in patients who received HDT. More recently, Santini et al 10 reported the results of a multicenter randomized study comparing conventional therapy and conventional therapy plus HDT with ABMT. Both DFS and progression-free survival were improved for HI risk and H risk patients who received HDT and ABMT. All these reports show that early consolidation with HDT and autologous bone marrow or stem cell support can significantly improve survival of these poor-risk patients.
We report the results of our experience in 126 consecutive NHL patients younger than 60 years, with an aggressive histology as defined in the REAL classification. All patients were HI risk or H risk groups in the Aa-IPI. They received treatment which consisted of either standard chemotherapy (CT) or HDT as front-line treatment. In this retrospective analysis, the treatment results are described and prognostic factors are evaluated.
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Patients and methods
Patients
Between 1984 and June 1996, 126 patients under 60 years of age with poor-risk aggressive NHL were analyzed for the study. Histological diagnosis was made using the Working Formulation, and then correlated to the REAL classification. All patients underwent physical examination, whole body CT scan, bone marrow biopsy, and lumbar puncture. Other examinations such as gastrointestinal or pulmonary endoscopies, bone scintigraphy, or liver biopsy were performed with regard to the site of disease. Some patients of this series were enrolled in investigational protocols. They were informed of the nature of the studies and informed consent was required in accordance with institutional guidelines.
Chemotherapy
Sixty-six patients received standard CT. This was CHOP for 14 patients, and 52 patients received a second or third generation chemotherapy regimen: 29 patients received m/M-BACOD, five patients received 12 weeks of MACOP-B, and 18 patients received either the LNH 84 or the LNH 87 regimen. The median number of cycles of combination chemotherapy administered was six (range, 5-10) for CHOP, and seven (range, 6-8) for m/M-BACOD. In the LNH 84 regimen, patients received four ACVBP courses with a 2-week interval, followed by a maintenance chemotherapy for 4 months for responder patients. 11 The LNH 87 regimen also included four ACVBP cycles, and patients were subsequently randomized between maintenance chemotherapy and ABMT. 8 For all patients receiving standard CT, the median duration of chemotherapy was 8 months (range, 6-10).
Sixty patients received HDT. Until April 1992, HDT consisted of autologous stem cell transplantation (35 patients). Patients were required to reach a partial response of у50% with front-line chemotherapy. This front-line chemotherapy was similar to that described in standard CT. The median time from diagnosis to autologous transplant was 6 months (range, [3] [4] [5] [6] [7] [8] . The myeloablative regimen consisted of BEAM (BCNU, VP16, cytarabine, melphalan) in all cases. From May 1992, HDT consisted of an intensive sequential chemotherapy (ISC) regimen with repeated peripheral blood stem cell (PBSC) support (25 patients). 12 Total duration of chemotherapy was 18 weeks for this regimen.
Response criteria
Response was evaluated 4 to 6 weeks after the last cycle of chemotherapy in the standard CT group, and 6 to 8 weeks after completion of treatment in the HDT group. CR was defined as the complete disappearance of all measurable and evaluable disease. In our study, partial response (PR) was defined as the complete disappearance of all physical and biological abnormalities, and a greater than 75% reduction of tumor mass. Biopsy or surgery of the residual mass was performed whenever the tumor was accessible. In the event of an intra-thoracic or intra-abdominal residual mass, we used CT scanning for assessment of response.
Statistical analysis
The 2 -test was used to compare patient characteristics. Overall survival (OS) was calculated from the date of diagnosis, death being scored as an event with censoring of other patients at the time of last follow-up. Event-free survival (EFS) was also calculated from the date of diagnosis, relapse or death being scored as an event, with censoring of other patients at the time of last follow-up. Disease-free survival (DFS) was calculated from the date of diagnosis, relapse being scored as an event, with censoring of other patients at the time of last follow-up. To draw survival curves, we used Kaplan and Meier estimates. Curves were compared by the log-rank test. Prognostic factors were assessed in a multivariate analysis by the Cox proportional hazard model in a forward stepwise regression. Survival rates and relative risk (RR) are presented with their 95% confidence intervals (CI).
Results
Patient characteristics
Patient characteristics are listed in Table 1 . There were 126 patients: 80 male (63%) and 46 female (37%). One hundred 
Response
An objective response (OR) was achieved in 99 patients (79%), with 64 patients (51%) in CR and 35 patients (28%) in PR. CR rates were 41% and 62% in the standard CT group and HDT group, respectively. Twenty-one patients (16%) did not achieve an OR, with 17 failures in the standard CT group (26%) and four failures in the HDT group (7%). Six patients of the standard CT group were not evaluable for response.
Relapse
Relapse after completion of an OR occurred in 37 patients (37%) overall, with 23 patients (53%) who relapsed being in the standard CT group and 14 (25%) in the HDT group (P = 0.003). Thirty-six relapses (97%) occurred within the 3 years following diagnosis, with 24 the 1st year (67%), nine the 2nd year (25%), and three the 3rd year (8%). We observed only one delayed relapse, in the 6th year. With a median follow-up of 61 months (range, 39-130), the 10-year OS for these 37 patients is 18%. Log-rank test.
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Survival Five-year survivals of patients in the two groups of treatment are listed in Table 2 . With a median follow-up of 63 months (range, 16-159), OS rate for all the patients was 52%. The 5-year EFS and DFS rates were 43%, and 61%. For the 66 patients in the standard CT group, the 5-year OS, EFS, and DFS rates were 31%, 24%, and 42%, respectively ( Figure 1) . The difference was statistically significant when compared to the HDT group, where OS, EFS, and DFS at 5 years were at 76%, 64%, and 76%, respectively ( Figure  1) . Patients who achieved CR with front-line therapy had a 5-year OS at 70%, while survival was 34% for patients who were not in CR (Figure 2 ).
Prognostic factors
On univariate analysis, the Aa-IPI score (2 vs 3), treatment group (standard CT vs HDT), and response to treatment (CR vs PR) were analyzed to determine whether they had an effect on OS. The most statistically significant factors for prolonged OS were HDT treatment (P Ͻ 0.0001), and CR achievement (P Ͻ 0.0001). Comparison of patients with two or three factors of the Aa-IPI revealed no difference in OS (P = 0.22). On multivariate analysis, both HDT treatment and CR status remained independently associated with survival (Table 3) .
Discussion
In this retrospective analysis, the two groups were well matched for histology, patient response to the tumor (PS), invasive potential of the tumor (Ann-Arbor stage), and the patient's ability to tolerate treatment (PS). We found a significant difference with regard to age and LDH, both well described as prognostic factors, and this could have influenced the differences in outcome between the two groups. All these listed clinical characteristics have been significantly associated with outcome in many previous studies. However, the relative risk could be identified by summing the number of risk factors present at diagnosis. The predictive model for aggressive NHL suggested that for younger patients (р60 years), the target population might be patients at high-intermediate and high risk as defined by the Aa-IPI. The 126 patients in our study were either HI or H risk. Moreover, consideration of Aa-IPI scores 2 and 3 showed no statistically significant difference between patients who received standard CT and those who underwent HDT. On the other hand, the use of several different chemotherapy regimens could also give heterogenous results, and In this retrospective series, the CR rate was higher for patients who received HDT. This difference might be due in part to the selection of responding patients who subsequently underwent HDT with ABMT/ASCT. However, unselected patients who received ISC with PBSC support as front-line treatment had also a high CR rate as previously reported. 12 HDT was also shown to be a statistically significant factor independently associated with prolonged survival. We observed more relapses in the standard CT group, suggesting that HDT can eradicate tumor cells more effectively than conventional chemotherapy. The prognosis of patients treated with standard CT in our series is poor, with a 5-year survival of 31%. This result is similar to those reported in other studies, and especially in the international NHL prognostic factors project. 7 Comparison of survival between HI and H risk groups patients revealed no difference, suggesting the poor outcome of this whole population was independent of the IPI score. Furthermore, the quality of the initial response to front-line therapy was often reported to be of prognostic value. 13 In our study, this parameter was also shown to be statistically significant in prolonged OS.
Recently, an international consensus conference on HDT with hematopoietic stem cell transplantation was held in France. The jury concluded that HDT is appropriate as front-line therapy in HI and H risk patients, and recommended the inclusion of patients in clinical trials.
14 Two randomized trials gave contradictory results, and showed no benefit of HDT over standard chemotherapy. 15, 16 This difference could be explained by the short duration of the induction sequence before HDT, which could significantly influence the quality of initial response. In fact, disease status at the time of HDT could include both complete and partial responses, and the probabilities of survival between these two groups of patients are not comparable. 17 On the other hand, there are two randomized studies which evaluated the prognostic value of response to standard induction therapy on survival. Unfortunately, both these trials were small and did not allow consensual recommendations. 18, 19 If randomized studies are needed to clarify the role of HDT in newly diagnosed poor prognosis NHL patients and the prognostic value of response, such methods may take many years to provide definitive conclusions. Pilot studies performed in specialized institutions are also warranted, and two merit more detailed discussion. The prospective cooperative trial reported by Vitolo et al 20 involved 50 patients with high-risk LCL. They were assigned to receive a programme which consisted of the following three phases: induction with 8 weeks of MACOP-B, intensification with high-dose cytarabine plus mitoxantrone and dexamethasone, and consolidation with BEAM therapy supported by ASCT. Thirty-six patients (72%) achieved CR at the completion of the regimen. With a median followup of 32 months, OS and DFS were at 56% and 69%, respectively. 20 In another pilot study, the role of HDT with ABMT/ASCT during first CR or PR was assessed in 52 patients with poor-risk intermediate and high-grade lymphoma. The authors reported a 3-year DFS of 89% in the subset of patients with LCL, with 92% and 87% in the HI risk and H risk groups, respectively. 21 Despite the small sample sizes, these two reports confirm that front-line HDT is necessary to improve CR rate, and subsequently, longterm DFS.
In conclusion, our results suggest that both initial CR achievement and HDT as front-line treatment are predictive factors for prolonged survival of patients with poor-risk LCL. Randomized phase III clinical trials should still be performed in this subgroup of patients.
